EN
Country: EN (United States)
Select country/region

Language

  • English

Message from the Executive Board

SICK REMAINS ON COURSE FOR SUSTAINABLE GROWTH WITH AN ACCELERATED PACE OF INNOVATION.

Demand for sensor products and solutions that generate high customer benefits, particularly through digitalization and AI applications, is increasing significantly. In the challenging fiscal year 2023, we were able to weather the supply crisis despite the adverse macroeconomic conditions, overcome unexpected market declines and increase sales and profit.

The earnings position of the SICK Group in the fiscal year 2023 was characterized by a positive sales and earnings trend. Sales revenue increased by around 5.4% overall. This was mainly due to changes in the product portfolio and increased sales volumes.

The EBIT margin in relation to sales increased by 0.7 percentage points year on year and was therefore in line with the forecast development. At the same time, the net return on sales increased by 0.3 percentage points year on year.

Demand for sensor products and applications was also pleasing in the past fiscal year. The broad positioning of the SICK Group proved its worth. The development of incoming orders in the business segments varied in intensity and was significantly lower than in the previous year. In particular, this reflects the reluctance to invest due to the uncertain economic development and a certain overheating in the previous year.

The Executive Board also changed in 2023. On October 16, 2023, Jan-H. Eberhardt took over the Finance & IT board portfolio from Markus Vatter, who had been managing the portfolio for 17 years. Among other things, Jan-H. Eberhardt will drive the company’s financial steering and IT landscape as part of our “SICK Beyond Borders” strategy. He will adapt the planning processes to better reflect the fast and dynamic market behavior and ensure the profitable growth of SICK. In addition, Jan-H. Eberhardt will focus on further increasing the security and resilience of our IT systems.

In the fiscal year 2023, SICK invested close to 12% of revenue in R&D activities. SICK is a highly innovative company. The number of employees in R&D and expenditure on R&D were increased and ensure outstanding results. With these investments, we are laying the foundations for future opportunities arising from new products and system solutions that can accelerate the company’s growth at an above-average rate.

In the past year, SICK as a team of all employees with unbridled enthusiasm and new solutions has once again inspired its customers. To accompany this annual report, we are publishing our latest magazine: PACE. We must keep adjusting our pace in order to gain and maintain a competitive edge for our customers and ourselves by using our acceleration forces in a meaningful way. The issues of our time are pressing and require accelerated solutions. Read in the PACE magazine how we are making our contribution with speed, commitment, and Sensor Intelligence.